Uveal Melanoma: Tebentafusp Treatment Study

We are studying whether the drug tebentafusp can help prevent cancer recurrence in patients with high-risk uveal melanoma after surgery or radiation. This trial also looks at the safety of the treatment compared to observation.

6-12 months Confirmation phase (III)No Placebo Standard Medicines InjectionOncologyOphthalmology

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What medicines are being studied?

Medicines that are officially approved for use in the European Union and considered safe by EMA. These medicines are already on the market and may be tested for new conditions or populations.

Kimmtrak

Kimmtrak is a medicine used to treat uveal melanoma, a rare form of eye cancer that has spread.

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Tebentafusp

Tebentafusp is an immunotherapy that redirects T cells to target and kill tumor cells in a type of eye melanoma.

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...

Cliniques Universitaires Saint-Luc

Oncology

Sint-Stevens-Woluwe, Belgium

Centre Antoine Lacassagne

Oncology

Nice, France

Institut Curie

Oncology

Paris, France

Sponsor: European Organisation For Research And Treatment Of Cancer

Last updated: Nov 26, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.